US FDA Data Integrity Guidance: ALCOA+ Principles And Compliance Best Practices

A shared login may seem harmless until an FDA investigator asks who changed a result. A missing chromatographic file, an unexplained reintegration, or an altered worksheet can cast doubt on far more than one test. It may undermine the evidence used to approve or reject an entire batch, as emphasized in the US FDA Data Integrity Guidance, which requires complete, accurate, and traceable records to support every CGMP decision.

FDA expects CGMP records to remain complete, consistent, accurate, traceable, and reconstructable throughout the data lifecycle. Enforcement has become more active. In fiscal year 2025, 112 warning letters describing violations of 21 CFR Part 211 appeared on the FDA website, the highest total reported in more than two decades. Deficiencies involving written procedures and batch records remained among the leading citations.ALCOA+ helps you translate these expectations into daily controls, but it is n

ot a separate FDA regulation. The sections ahead explain its 9 principles, applicable FDA requirements, paper and electronic record controls, audit trail review, risk assessment, remediation, and inspection preparation.

Source: https://qualysec.com/us-fda ...